-

Axoft Unveils Meaningful Clinical Momentum of Its Ultra-Soft Fleuron™ Brain Computer Interface Probes

Initial human and animal data from Mass General Brigham and The Panama Clinic show that Axoft’s probes are safe, atraumatic and smoothly move with the brain to provide high-resolution neural data with high stability and high yield

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axoft, a neurotechnology company, today announced multiple data milestones from ongoing clinical use of its ultra-soft Fleuron™ Brain Computer Interface (BCI) depth probes at Mass General Brigham (MGB) and The Panama Clinic. Built to leverage the naturally scalable language of the brain, Axoft’s high-density BCIs use the company’s proprietary Fleuron material, which enables high quality neural data capture over longer periods of time due to the material’s superior biocompatibility. Axoft’s BCIs have already demonstrated the ability to safely decode brain signals, and offer a path for improving the standard of care for prognosis and communication in disorders of consciousness.

“Every year in the U.S., traumatic brain injuries lead to 2.9 million emergency room visits, with many patients ending up in an unresponsive state. Physicians will look for signs of consciousness by prompting a response, but consciousness and the ability to respond are not the same,” said Dr. Paul Le Floch, co-founder and CEO of Axoft. “Axoft is measuring consciousness directly from the brain to provide a much-needed voice to the almost half (43%) of neuro-ICU patients who are misdiagnosed when it comes to their state of consciousness. This clinical momentum demonstrates our progress in safely collecting vital neural data to transform how patients who are in comas, vegetative states or minimally conscious states are assessed and treated, with long-term applications potentially extending into treatments for epilepsy, movement disorders and other neurological conditions.”

Axoft’s latest clinical results include:

  • Five human patients at The Panama Clinic were acutely implanted with Axoft’s Fleuron probe in the cortex with classification of the anesthetic state. In the first four patients, two were observed in the awake state and two were observed asleep, which then predicted in the fifth patient a proof of concept on zero shot decoding of consciousness in real time. These results relating to Axoft’s work in disorders of consciousness were presented by Axoft’s Jordy Tasserie, PhD at the Neurocritical Care Society’s annual meeting, which took place October 20 - 23, 2026 in Seattle.
  • Seven human patients across MGB and The Panama Clinic were implanted with Axoft’s Fleuron probe during planned surgery for tumor or hematoma removal. Neural data collected indicated high stability and high data yield with up to 85% of channels with a single-unit-spike-SNR. Further findings were presented by Axoft’s Jessica Grossman, MD at the 76th annual Congress of Neurological Surgeons, which took place October 31 - November 4, 2026 in Washington D.C.
  • A comparison of porcine and human data from MGB showed that Axoft’s Fleuron probes move with the brain to provide stable neural data by eliminating pulsation-driven single-unit micromotion. The data was confirmed with an intraoperative microscope and reveal how stable local field potentials from single neurons don’t require post-hoc registration. Axoft’s Jake Swann, PhD, along with MGB’s Angelique Paulk, PhD, presented these data at the Society for Neuroscience, which took place November 14 - 18, 2026 in Washington D.C.

These clinical results come during a period of continued momentum for the company. Following the close of its $55 million Series A round in April, Axoft was named a MedTech Breakthrough Award winner, selected as a finalist for the Mid-Stage Grand Prize 2026 MedTech Innovator cohort and named to Fast Company’s Next Big Things in Tech list. In August, the company introduced the latest addition to its advanced polymer portfolio: Fleuron Water Invisible Soft Elastomer (WISE), a UV-curable material engineered to “disappear” in water when submerged by matching water’s refractive index, and enable super-resolution imaging of biological samples and living organisms. Axoft also recently welcomed Alex Zhavoronkov, founder and CEO of Insilico Medicine, as an angel investor.

About Axoft

Founded in 2021 and headquartered in Cambridge, Massachusetts, Axoft is building implantable Brain-Computer Interfaces (iBCIs) leveraging bio-inspired materials to enable a seamless interface between the brain and electronics, and allow for measurement and stimulation at high-resolution in any brain region. Axoft is on a mission to unlock new treatments for patients suffering from neurological disorders by producing iBCIs that answer critical unmet needs. For more information, visit www.axoft.us or follow us on LinkedIn.

Contacts

Media Contact
Kerry Walker
kerry@walkercomms.com

Axoft


Release Versions

Contacts

Media Contact
Kerry Walker
kerry@walkercomms.com

More News From Axoft

Axoft Introduces Fleuron® WISE, the Latest Addition to its Advanced Polymer Portfolio

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axoft, a neurotechnology company, today introduced the latest addition to its advanced polymer portfolio: Fleuron® Water Invisible Soft Elastomer (WISE), a UV-curable material engineered to “disappear” in water when submerged by matching water’s refractive index. Ultra-soft, flexible and impermeable to water, WISE enables dramatically reduced optical aberrations and sharper, higher-resolution imaging for aqueous samples. The novel material is commercially avai...

Axoft Secures $55M Series A to Advance Clinical Trials Globally for its Bio-Inspired, Implantable Brain-Computer Interface

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axoft, a neurotechnology company, today announced it has raised an oversubscribed $55 million Series A led by C.P. Group Innovation. Alumni Ventures, the Stanford President’s Venture Fund, Hillhouse Investment and Gaorong Ventures also participated in the round. With more than $60 million in total funding raised, Axoft will use the capital to expand its current clinical trials globally and progress U.S. regulatory approval of its implantable Brain-Computer Int...

Axoft Successfully Completes First Four Cases of First-in-Human Clinical Study of its Ultrasoft, High-Density Brain-Computer Interface

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axoft, a neurotechnology company, today announced preliminary results from its first-in-human clinical study, FINESSE, which began just two and a half years after the company’s seed funding round and was designed to show that Axoft’s implantable brain computer interfaces (iBCIs) can safely decode brain signals. The iBCIs in the study are made using Axoft’s novel Fleuron™ material, which is 10,000x softer than the polyimide used in existing iBCIs, offers superi...
Back to Newsroom